Their advisers argued that pooling of resources would bring forward the great day when the human genome sequence could be declared complete. Sulston was clearly embarrassed by the involvement of government publicity machines but lived in constant fear that his funding might be withdrawn or cut back, as siren voices persuaded the decision-makers that the combination of business efficiency and commercial funding would get the job done faster and at no cost to the public purse. The 'public' cooperative took the view that, since commercial funding was ultimately dependent on recouping research costs by exploitation of the findings, and since exploitation depended on patents or other forms of protection of proprietary interests, Celera could never make their data freely available to all who wanted them. The partnership was therefore bound to be unequal, with Celera (and their backers) benefiting from information placed on an open database but releasing very little new information themselves. As Sulston tells it, that is essentially what happened. The undertakings given by Celera were, in his view, amenable to clever legalistic reinterpretations or, at least, to interminable delays. He also believes that the 'shotgun cloning and sequencing' techniques adopted by Celera were fundamentally flawed and, without the mass of data provided by Sulston and his international colleagues, would have been virtually useless.
The 'good guys' recognized that the most effective way to frustrate the predatory claims of Celera was to pump information into the public database so fast that many applications for gene patents would be disallowed on the grounds of prior disclosure. That, of course, depended on continued adequate funding of the public research effort. An unlikely hero of the story is the Wellcome Trust, perhaps the only independent body with the financial muscle to support an enterprise on this scale. They did so, nailing their colours to the mast of freedom of access to scientific information, and were probably influential in persuading the US National Institutes of Health to do likewise. Had the project been less far advanced when Celera entered the lists, or had the international cooperative failed to maintain their phenomenal rate of data generation, it is possible that political and commercial pressures would have closed down the publicly funded programme.
There is unquestionably much bitterness, as well as satisfaction, in Sulston's recall of the events leading to publication of the first draft of the human genome. He has derived, perhaps from his clergyman father, a keen sense of right and wrong and is passionately concerned to alert politicians and public to the dangers of a Faustian pact between science and big business. He sees 'private ownership' of scientific information as the enemy of progress and, for those who may be seduced by the notion that pharmaceutical companies or other commercial concerns will pick up the bill, he argues forcibly that there is no such thing as a free lunch. His own life story and his experience of the Human Genome Project provide an appropriate stage on which to rehearse these wider issues. His co-author, Georgina Ferry, unobtrusively adds a professional writer's flair to a tale that retains its personal flavour and grips the reader without being sensationalized. Whether the issues and their implications are sufficiently clear to a non-scientist (in particular to politicians who will make the relevant decisions) only time will tell. They certainly matter, and the outcome of the battle that Sulston describes here is going to affect all our lives most profoundly. He has done a considerable service in presenting his view of the world of 'big science' and big business-a good and thought-provoking read. Is the desire to prevent or cure disease an ethical trump card that overcomes any moral objection to the methods used? Or are there ethical boundaries that ought never to be transgressed, even for the best of reasons? These are the questions underlying the debate on cloning and stem cell research, which burgeoned in 1997 after the cloning of Dolly the sheep. This anthology, a chronological series of essays by politicians, lawyers, academics and journalists, follows the debate over whether the United States Government should ban human cloning and the harvesting of stem cells from human embryos.
The sixty contributions-from Brave New World to the terrorist attacks of 11 September-have been sparingly edited. Consequently, one is left wondering at what stage some of the errors were introduced: did President Bush really say that stem cells have the potential to develop in (rather than into) all tissues? As the debate becomes more polarized, it is easy to lose sight of the facts. Annotations would have been invaluable: as it is, the reader has only very brief biographical details of the contributors to help place their work in context. In the case of Rael, we learn that he 'believes he was contacted in 1973 by aliens', and from this we might deduce that his testimony to the House of Representatives is not the most reliable source of information, but bias in other contributions is less obvious. The claim that conjoined twins form by partial separation of two primitive streaks goes unchallenged (there is at least as much evidence that they form by partial fusion); as does the statement that toads can be cloned from mature intestinal cell nuclei, despite later work that failed to replicate these findings. Some ill-informed pieces of journalism are included (perhaps to show the different levels of debate).
Arguments against experimentation with human embryos are essentially emotional: it is morally repugnant, barbarous, and against nature. J Bottum writes in 'The Pig-Man Cometh':
'You can't say we weren't warned. This is the island of Dr. Moreaux. This is the brave new world. This is Dr. Frankenstein's chamber. This is Dr. Jekyll's room. This is Satan's Pandemonium, the city of self-destruction the rebel angels wrought in their all-consuming pride.'
As Leon R Kass, Chairman of the President's Council on Bioethics, observes in one of several perceptive essays, feelings such as these cannot be dismissed lightly: even people who accept the unlimited use of embryos for research would recoil from the idea of eating them-human tissue commands a certain (though perhaps irrational) respect.
Proponents of stem cell research with the courage of their convictions argue that the need to find new cures justifies any reasonable means, a case passionately made by and on behalf of those with neurodegenerative diseases. Most people, they argue, will accept some loss of human life in a just cause such as a war: why not then use 'surplus' embryos for the best of all causes-the alleviation of human suffering. James D Watson (the Nobel Prize often seems to confer a licence to say what one really thinks) advocated 'no limits' to 'negative eugenics'. Nothing less than the total elimination of genetic disease is the target.
Some pro-research writers attempt to evade the problem by redefining the early embryo as legally nonhuman. If this can be achieved, consciences are mollifiedthe embryos are not really human after all (by a similar strategy a pill that prevents implantation, but not conception, is legally a contraceptive). But this is dangerous ground: the road to medical experimentation on human subjects has always begun with their reclassification as subhuman. As the editors William Kristol and Eric Cohen suggest in their concluding essay, might 'an absolute devotion to health . . . invite civilised nations to tolerate, even celebrate, morally questionable pursuits (like cloning human embryos for research or harvesting organs)?'
Although the debate summarized by these essays sometimes seems overly politicized, at least there was a debate, culminating in President Bush's address to the American people in 2001 (and a compromise solutionstem cell research is permitted, but not publicly funded). Perhaps the most telling question is why a comparable level of debate has not occurred in the UK. The Future is Now does not contain enough background information to enable the general reader fully to understand the problems, but for those who already know the science it is a good introduction to some of the wider issues. It may not be long before therapies derived from embryo research become available, and as James Watson wrote: 'if we do not think about it now, the possibility of our having a free choice will one day suddenly be gone'. Dr Knottnerus believes that, while ample attention has been given to the evidence basis for therapeutics, formal evaluation of diagnostic methods has been unjustly neglected. With The Evidence Base of Clinical Diagnosis he aims to help not only researchers but also clinicians and students who wish to get a grip on the scientific principles. One would be hard pushed to imagine a better example of globalization than this book, published by the BMJ in London with authors drawn from the Netherlands, the USA and Australia, type set in India and printed in Spain.
A W Bates
Contributors discuss the objectives of diagnostic testing and the challenges of designing studies to evaluate these procedures. The various options are dealt with in detailfor example, the cross-sectional study, the randomized controlled trial, and the before-and-after study as well as the systematic review-with a warning that results cannot always be extrapolated from one environment to another, such as hospital to primary care. The reader is offered formulas for calculating sensitivity, specificity, likelihood ratios and other indices that will aid analysis. A chapter on computer-aided diagnosis adopts a general approach, and I would have liked more examples of how computers can change clinical practice (if they do). Of particular interest to
